Implications of nanotechnology for the treatment of cancer: Recent advances
Klochkov S. G., Neganova M. E., Nikolenko V. N., Che`n` K., Somasundaram S. G., Kirkland C. E., Aliev G.
Seminars in Cancer Biology
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.semcancer.2019.08.028
Аннотация:
The use of nanoparticles dramatically increases the safety and efficacy of the most common anticancer drugs. The main advantages of nano-drugs and delivery systems based on nano-technology are effective targeting, delayed release, increased half-life, and less systemic toxicity. The use of nano-carriers has led to significant improvements in drug delivery to targets compared with traditional administration of these drugs. In this review, the main tendencies in nano-drug formulations as well as factors limiting their use in clinical settings are discussed. Additionally, the current status of approved nano-drugs for cancer treatment is reviewed. © 2019 Elsevier Ltd
Ключевые слова:
Cancer; Drug delivery; Nano-drugs; Nano-technology; Oncotarget
Язык текста: Английский
ISSN: 1096-3650
Klochkov S. G.
Neganova M. E.
Nikolenko V. N. Vladimir Nikolaevich 1956-
Che`n` K. Ko 1990-
Somasundaram S. G.
Kirkland C. E.
Aliev G. Gyumrakh 1958-
Клочков С. Г.
Неганова М. Е.
Николенко В. Н. Владимир Николаевич 1956-
Чэнь К. Ко 1990-
Сомасундарам С. Г.
Киркланд C. Е.
Алиев Г. Гюмрах 1958-
Implications of nanotechnology for the treatment of cancer: Recent advances
Текст визуальный непосредственный
Seminars in Cancer Biology
Academic Press
Обзор
Cancer Drug delivery Nano-drugs Nano-technology Oncotarget
The use of nanoparticles dramatically increases the safety and efficacy of the most common anticancer drugs. The main advantages of nano-drugs and delivery systems based on nano-technology are effective targeting, delayed release, increased half-life, and less systemic toxicity. The use of nano-carriers has led to significant improvements in drug delivery to targets compared with traditional administration of these drugs. In this review, the main tendencies in nano-drug formulations as well as factors limiting their use in clinical settings are discussed. Additionally, the current status of approved nano-drugs for cancer treatment is reviewed. © 2019 Elsevier Ltd